99 related articles for article (PubMed ID: 6172340)
1. [Adjuvant chemotherapy in malignant melanoma after pretherapeutic sensitivity testing].
Zaumseil RP; Wohlrab W; Fiedler H; Wozniak KD
Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(5):721-4. PubMed ID: 6172340
[No Abstract] [Full Text] [Related]
2. [Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
Pullmann H; Muth M
Z Hautkr; 1982 Feb; 57(4):294-7. PubMed ID: 7080583
[No Abstract] [Full Text] [Related]
3. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
4. [Chemotherapy of malignant melanoma].
Karakousis CP
Chirurg; 1986 Oct; 57(10):606-11. PubMed ID: 3792110
[No Abstract] [Full Text] [Related]
5. [Chemotherapy of malignant melanomas].
Gallmeier WM
Haematol Blood Transfus; 1978; 21():293-302. PubMed ID: 367896
[No Abstract] [Full Text] [Related]
6. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
[TBL] [Abstract][Full Text] [Related]
7. Current concepts in the management of malignant melanoma.
Lichtenfeld JL
Am J Med Sci; 1976; 272(2):185-95. PubMed ID: 1008080
[No Abstract] [Full Text] [Related]
8. Results of adjuvant BCG immunotherapy in malignant melanoma.
Wätzig V; Knopf B
Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
[TBL] [Abstract][Full Text] [Related]
9. [Results of immunochemotherapy in malignant melanoma].
Duchková H; Richter J; Kubíková M; Peska J; Ragan J; Vohryzková E; Hrivnáková J; Kvasnicka J
Cesk Dermatol; 1980 Aug; 55(4):277-80. PubMed ID: 7407970
[No Abstract] [Full Text] [Related]
10. Letter: Chemoimmunotherapy of malignant melanoma.
N Engl J Med; 1975 Jan; 292(3):159-60. PubMed ID: 1196343
[No Abstract] [Full Text] [Related]
11. [5-year results of a chemo-immunotherapeutic treatment in stage-I and -II malignant melanoma].
Comella G; Mastro AA; Comella P; Castello G; De Simone G; Cerra R; Zarrilli D
Minerva Med; 1986 Mar; 77(13):507-10. PubMed ID: 3703343
[No Abstract] [Full Text] [Related]
12. Changes in the rosette forming capacity of lymphocytes after surgery or surgery and immunochemotherapy of malignant melanoma in man.
Hadjikirova M; Boeva M; Ikonopisov R
Biomed Pharmacother; 1982; 36(5):257-9. PubMed ID: 7168802
[TBL] [Abstract][Full Text] [Related]
13. Results of a nonrandomized trial in malignant melanoma patients (Clark's stages III--V) treated by post-surgical chemoimmunotherapy.
Serrou B; Pujol H; Domas J; Gauci L
Recent Results Cancer Res; 1978; 68():363-6. PubMed ID: 752871
[No Abstract] [Full Text] [Related]
14. Adjuvant immunotherapy of malignant melanoma.
Aranha GV; McKhann CF; Grage TB; Gunnarsson A; Simmons RL
Cancer; 1979 Apr; 43(4):1297-303. PubMed ID: 445331
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024
[TBL] [Abstract][Full Text] [Related]
16. [Multiple BCG-induced ulcers after subcutaneous vaccination in the framework of immunochemotherapy in malignant melanoma].
Korting HC; Strasser S; Konz B
Hautarzt; 1988 Mar; 39(3):170-3. PubMed ID: 3378889
[TBL] [Abstract][Full Text] [Related]
17. [Immunological aspects in the treatment of malignant melanoma].
Cascinelli N; Vaglini M; Rovini D; Orefice S; Marolda R; Veronesi U
Minerva Med; 1982 Apr; 73(18):1233-40. PubMed ID: 7078802
[No Abstract] [Full Text] [Related]
18. Systemic therapy of malignant melanoma.
Seeger J; Richman SP; Allegra JC
Med Clin North Am; 1986 Jan; 70(1):89-94. PubMed ID: 3510351
[TBL] [Abstract][Full Text] [Related]
19. Value of adjuvant therapy with bacille Calmette Guerin (BCG) or dimethl triazeno imidazole carboximide (DTIC) in the control of minimal residual disease in stage II melanoma.
Peter HH; Deutschmann KE; Deinhardt J; Deicher H
Recent Results Cancer Res; 1978; 68():367-74. PubMed ID: 752872
[No Abstract] [Full Text] [Related]
20. Combined modality therapy of malignant melanoma.
Hersh EM; Gutterman JU; McBride CM
World J Surg; 1979 Jul; 3(3):329-43. PubMed ID: 382647
[No Abstract] [Full Text] [Related]
[Next] [New Search]
